SPY301.89-1.08 -0.36%
DIA253.11-1.24 -0.49%
IXIC9,367.62-1.37 -0.01%

Intercept Pharmaceuticals Q1 EPS $(2.860) Beats $(2.950) Estimate, Sales $72.652M Beat $69.660M Estimate

Intercept Pharmaceuticals (NASDAQ:ICPT) reported quarterly losses of $(2.860) per share which beat the analyst consensus estimate of $(2.950) by 3.05 percent. This is a 5.61 percent increase over losses of $(3.030) per

Benzinga · 05/11/2020 11:21

Intercept Pharmaceuticals (NASDAQ:ICPT) reported quarterly losses of $(2.860) per share which beat the analyst consensus estimate of $(2.950) by 3.05 percent. This is a 5.61 percent increase over losses of $(3.030) per share from the same period last year. The company reported quarterly sales of $72.652 million which beat the analyst consensus estimate of $69.660 million by 4.30 percent. This is a 39.04 percent increase over sales of $52.252 million the same period last year.